ATTRibute-CM
2024
Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Cardiomyopathy
In 632 patients with transthyretin amyloid cardiomyopathy, acoramidis improved a hierarchical composite of death, CV hospitalisation, NT-proBNP and 6-minute walk distance compared with placebo.
Result
Efficacy: Hierarchical composite (all-cause death, CV hospitalisation, NT-proBNP, 6-minute walk) at 30 monthswin ratio 1.8 (95% CI 1.4-2.2) · P < 0.001
Below 1 favours placebo, above 1 favours acoramidis.
Also reported: Acoramidis superior on the hierarchical primary endpoint , driven largely by mortality and CV hospitalisation.
- Subtopic
- TTR stabiliser
- Design
- Double-blind placebo-controlled RCT, phase 3
- Relevance
- Supporting: context rather than must-know.
- Source
- Gillmore JD, et al. N Engl J Med. 2024;390(2):132-142.doi 10.1056/NEJMoa2305434
Discussion & critique
Win-ratio composite harder to interpret clinically than event rates, and high background tafamidis use complicates comparison. Expanded disease-modifying options for ATTR-CM as a second-generation TTR stabiliser.